Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary)
Indications Breast cancer; HER2 positive breast cancer
Focus Pharmacodynamics
Acronyms SIGNAL

Most Recent Events

01 Aug 2017 Results (n=5502) assessing sequential versus concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer using patient data from NCT00381901 and SIGNAL trials published in the European Journal of Cancer
27 Nov 2016 New trial record
11 Oct 2016 Results evaluating the impact of HER expression levels in the PHARE/SIGNAL cohort (n=5474; HER2+) presented at the 41st European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight